Biolyn Pharmaceutical B.V.
Retatrutide pharmaceutical vial
In Stock
CAS: 2381089-83-2

Retatrutide

Triple-Agonist GIP/GLP-1/Glucagon Receptor Peptide

Retatrutide (LY3437943) is a novel triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Biolyn supplies research-grade and API-grade Retatrutide to qualified research institutions, pharmaceutical developers, and B2B formulation partners across Europe and globally.

Technical Profile

A 39-amino acid synthetic peptide with a C20 fatty diacid moiety linked via a linker to Lys13. Produced via solid-phase peptide synthesis (SPPS) with stringent purification protocols ensuring >99% chromatographic purity.

CAS Number2381089-83-2
Molecular Weight4,113.58 g/mol
Molecular FormulaC190H302N56O53S2
Purity>99% (HPLC)
FormLyophilized Powder
Storage-20C, desiccated, protected from light
Applications
Metabolic disease researchGLP-1/GIP/Glucagon receptor binding studiesPreclinical pharmacologyAPI for pharmaceutical formulation (B2B)Investigational compound development
GHK-CuSemaglutide
Biolyn Pharmaceutical B.V.
Age Verification & Research Use

Please confirm before you continue

Biolyn Pharmaceutical B.V. supplies products strictly to businesses and institutions for laboratory and research use. Our products are not for human or veterinary consumption.

  • I am at least 18 years of age.
  • I represent a business, research institution, or licensed manufacturer.
  • I understand all products are supplied for laboratory and research purposes only — not for human or veterinary consumption.

By entering you accept our research-use terms. B2B only. No retail / No B2C.